Fractyl Health, Inc. Common Stock
Here’s whether Fractyl Health, Inc. Common Stock (GUTS) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.
Positives: above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+12.12% over 10 days); 3-month momentum positive (+38.8%). Concerns: trading below the 200-day MA (long-term downtrend); weak 1-year return of -65.0%. Currently 77.6% off its 52-week high. Score: +0/7.
GUTS is trading below its 200-day MA ($1.10) — a key warning sign the longer-term trend is under pressure. An RSI of 33.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -65.0% compares to +24.4% for SPY (trailed the market by 89.4%). The current 77.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.